NeoGenomics: Chris Smith

NeoGenomics has appointed Chris Smith as CEO and a member of its board of directors effective Aug. 15. Concurrently, board chair and interim CEO Lynn Tetrault will resume her role as independent chair of the board while assisting in the transition of responsibilities.

Smith joins NeoGenomics after serving as CEO of Ortho Clinical Diagnostics from 2019 to May 2022, during which time the firm raised $1.45 billion in funding in an initial public offering. Prior to Ortho Clinical, Smith held key executive leadership positions at Cochlear Limited. He has also served as CEO in residence at global private equity firm Warburg Pincus and Global Group President at Gyrus Group, as well as in a variety of leadership roles at Abbott, KCI, Prism and Cardinal Health. He holds a BS from Texas A&M University.